Muscle-Targeting Oligonucleotide-Antibody Complexes for DMPK Knockdown
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myotonic dystrophy type 1 (DM1) are inadequate, with no effective treatments available to address the underlying genetic cause of the disease, which involves toxic RNA repeats leading to protein sequestration and loss-of-function phenotypes.
Innovation Solution
Development of muscle-targeting complexes comprising an oligonucleotide covalently linked to an anti-transferrin receptor 1 (TfR1) antibody, formulated with tris(hydroxymethyl)aminomethane and sucrose, to specifically deliver the oligonucleotide to target cells and reduce DMPK expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for myotonic dystrophy type 1, then supportive care and symptom management are provided, but no effective treatment addresses the underlying genetic cause
Solution Approach 1:
The patent extracts and targets the toxic RNA repeats containing the CTG trinucleotide expansion specifically within the DMPK gene. By using oligonucleotide complexes that bind to these expanded repeats, the invention selectively removes or silences the harmful genetic element, preventing protein sequestration and restoring normal muscle function.
Solution Approach 2:
The patent employs oligonucleotide complexes as intermediary molecules that mediate between the toxic RNA repeats and the cellular machinery. These complexes include modified oligonucleotides that can bind to the expanded CTG repeats and facilitate their degradation or silencing, thereby indirectly eliminating the harmful effect without directly attacking the genetic code itself.
2Reliability
If oligonucleotide complexes are designed to target DMPK expression, then therapeutic effect is achieved, but delivery specificity to muscle tissues must be ensured
Solution Approach 1:
The patent segments the delivery system into distinct functional components: (1) oligonucleotide payloads that bind to and silence DMPK RNA, (2) carrier molecules that facilitate cellular uptake, and (3) targeting moieties that direct the complex to muscle-specific receptors. This segmentation allows each component to be optimized independently for its specific function while working together as an integrated therapeutic system.
Solution Approach 2:
The patent applies local quality by incorporating muscle-specific targeting elements into the oligonucleotide complexes. The complexes are designed with affinity for muscle cell surface receptors or intracellular muscle-specific proteins, ensuring that the therapeutic oligonucleotides are delivered preferentially to muscle tissues where DMPK expression needs to be silenced, rather than distributing them uniformly throughout the body.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The complexes effectively knock down DMPK expression and correct splicing defects in muscle tissues, providing a therapeutic approach for myotonic dystrophy.
Implementation Method 1
an anti-transferrin receptor 1 (TfR1) antibody... specifically deliver the oligonucleotide to target cells
Data Source
AI summary
Aspects of the disclosure relate to complexes and other aspects relate to formulations (e.g., aqueous, lyophilized forms) comprising such complexes comprising an oligonucleotide (e.g., useful for targeting DMPK) covalently linked to an antibody (e.g., anti-TfR1 antibody).